Scott Rosman
Community Health · Binghamton, NYNPI 1568750651
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,037 of the $12,697 with a category attached, or 79.0%. 28 manufacturers reported payments, led by Viiv Healthcare Company at 31.6% of the total. Reporting peaked in 2023 at $4,925 and has fallen 57.8% since, to $2,077 in 2025. Among community health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 486 payments — averaging $26.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$4K
- AbbVie$3K
- Gilead$1K
- GSK$943
- Novo Nordisk$485
- Merck$478
- plus $3K from 22 others
What the payments were for
- Consulting fees$2,66021%
- Food & beverage$10,03779%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 65 | $4,006 |
| AbbVie | 131 | $2,693 |
| Gilead | 38 | $1,482 |
| GSK | 62 | $943 |
| Novo Nordisk | 30 | $485 |
| Merck | 25 | $478 |
| Novartis | 22 | $347 |
| AstraZeneca | 14 | $300 |
| Boehringer Ingelheim | 17 | $256 |
| Pfizer | 16 | $237 |
| Abbott | 14 | $228 |
| Johnson & Johnson(2 entities) | 9 | $204 |
| Exact Sciences | 8 | $177 |
| Amgen | 8 | $169 |
| Astellas Pharma US Inc | 1 | $135 |
| Lilly USA, LLC | 5 | $109 |
| EMD Serono, Inc. | 4 | $73 |
| Neurocrine Biosciences, Inc. | 2 | $51 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Bayer | 2 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Indivior Inc. | 1 | $35 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Verona Pharma, Inc. | 1 | $29 |
| Halozyme Inc | 1 | $26 |
| Alkermes, Inc. | 1 | $22 |
| Braeburn Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,697 in reported general payments places this provider in the 95th percentile of 21 community health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 385 | $1,516,591 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 64 | $329,106 |
| DescovyEmtricitabine/Tenofov Alafenam | 100 | $245,450 |
| DovatoDolutegravir Sodium/Lamivudine | 72 | $213,456 |
| TivicayDolutegravir Sodium | 76 | $203,352 |
| JulucaDolutegravir/Rilpivirine | 51 | $167,868 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 31 | $129,096 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 29 | $123,789 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 112 | $120,986 |
| IsentressRaltegravir Potassium | 53 | $101,138 |
| EliquisApixaban | 104 | $94,664 |
| PrezcobixDarunavir/Cobicistat | 38 | $88,151 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 23 | $85,529 |
| OzempicSemaglutide | 67 | $69,255 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 53 | $69,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $1,482 | $1,847,570508 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Juluca, Triumeq | $4,006 | $713,772230 claims |
| MerckIsentress, Pifeltro, Janumet Xr, Isentress Hd | $478 | $233,758154 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Glyxambi | $256 | $162,082175 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $943 | $145,458161 claims |
| PfizerEliquis, Selzentry | $237 | $137,252129 claims |
| Lilly USA, LLCMounjaro, Trulicity | $109 | $101,15486 claims |
| Novo NordiskOzempic, Rybelsus | $485 | $90,42779 claims |
| Johnson & JohnsonPrezcobix | $204 | $88,15138 claims |
| AbbVieCreon, Vraylar, Linzess | $2,693 | $60,86952 claims |
| NovartisEntresto | $347 | $53,11341 claims |
| AstraZenecaFarxiga | $300 | $44,62248 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 community health providers in New York.
Other community health in Binghamton
- Danielle MejiasBinghamton$1K
- Stacey RosmanBinghamton$457
- Terry HardingBinghamton$23
- Edwin TorresNew York$76K
- Sharon PearceDolgeville$3K
- Megan CoghlanSyracuse$529
- Desiree DarrisawNew York$506
- Mallory FurnissWest Amherst$442
- Dayle BowerVestal$416
- Dawn LawyerNew York$305
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.